Back to Search
RACHID BAZ, MD
MD
Hematology & Oncology Physician
NPI: 1831393875IndividualAccepts Medicare
Specialties, Licenses & Credentials
Hematology & Oncology PhysicianPrimary
Internal Medicine — Hematology & Oncology
Code: 207RH0003X
35085773(OH)ME101500(FL)
Education
OTHER
Class of 2000
Research & Publications (20)
Clinical significance of cyclin D1, fibroblast growth factor receptor 3, and p53 immunohistochemistry in plasma cell myeloma treated with a thalidomide-based regimen.
PMID 19070887·Hum Pathol·2009
8-other
An association between renal cell carcinoma and multiple myeloma: a case series and clinical implications.
PMID 17970789·BJU Int·2008
5-case
Impact of socioeconomic status and distance from treatment center on survival in patients receiving remission induction therapy for newly diagnosed acute myeloid leukemia.
PMID 17727945·Leuk Res·2008
8-other
Increased C-kit intensity is a poor prognostic factor for progression-free and overall survival in patients with newly diagnosed AML.
PMID 17928050·Leuk Res·2008
8-other
Clinical factors associated with outcome in patients with metastatic clear-cell renal cell carcinoma treated with vascular endothelial growth factor-targeted therapy.
PMID 17577222·Cancer·2007
8-other
Can zinc be an adjuvant therapy for juvenile onset recurrent respiratory papillomatosis?
PMID 17560665·Int J Pediatr Otorhinolaryngol·2007
5-case
Lenalidomide: the emerging role of a novel targeted agent in malignancies.
PMID 17353946·Drugs Today (Barc)·2007
6-review
Recombinant human erythropoietin is associated with increased overall survival in patients with multiple myeloma.
PMID 17148935·Acta Haematol·2007
8-other
Combination of rituximab and oral melphalan and prednisone in newly diagnosed multiple myeloma.
PMID 18067008·Leuk Lymphoma·2007
3-trial
G1P3, an IFN-induced survival factor, antagonizes TRAIL-induced apoptosis in human myeloma cells.
PMID 17823654·J Clin Invest·2007
8-other
Impact of remission induction chemotherapy on survival in older adults with acute myeloid leukemia.
PMID 17724726·Cancer·2007
4-observational
Prognostic factors associated with long-term survival in previously untreated metastatic renal cell carcinoma.
PMID 17060490·Ann Oncol·2007
8-other
Phase II study of lenalidomide in patients with metastatic renal cell carcinoma.
PMID 17075879·Cancer·2006
3-trial
Lenalidomide and pegylated liposomal doxorubicin-based chemotherapy for relapsed or refractory multiple myeloma: safety and efficacy.
PMID 16980599·Ann Oncol·2006
3-trial
The role of race, socioeconomic status, and distance traveled on the outcome of African-American patients with multiple myeloma.
PMID 16963396·Haematologica·2006
4-observational
Does low-dose aspirin have antineoplastic effects in multiple myeloma?
PMID 16848779·Br J Haematol·2006
8-other
Phase 2 study of pegylated liposomal doxorubicin, vincristine, decreased-frequency dexamethasone, and thalidomide in newly diagnosed and relapsed-refractory multiple myeloma.
PMID 16835968·Mayo Clin Proc·2006
3-trial
Efficacy and safety results with the combination therapy of arsenic trioxide, dexamethasone, and ascorbic acid in multiple myeloma patients: a phase 2 trial.
PMID 16720927·Med Oncol·2006
3-trial
The role of aspirin in the prevention of thrombotic complications of thalidomide and anthracycline-based chemotherapy for multiple myeloma.
PMID 16342649·Mayo Clin Proc·2005
3-trial
Prevalence of vitamin B12 deficiency in patients with plasma cell dyscrasias: a retrospective review.
PMID 15305411·Cancer·2004
8-other
Data courtesy of the U.S. National Library of Medicine (NLM). Ltrl is not affiliated with or endorsed by NLM.
Contact & Hours
- Address
- 12902 USF MAGNOLIA DR, FOB3
TAMPA, FL 33612 - Phone
- (813) 745-4623
Quick Facts
- NPI
- 1831393875
- Entity Type
- Individual
- Gender
- Male
- Medicare
- Accepted
- Specialties
- 2
- Locations
- 1
- Years in Practice
- 26
- Publications
- 20
Are you this provider?
Claim Your Profile